Acute Hemorrhagic Leukoencephalitis
Acute hemorrhagic leukoencephalitis (AHLE) is a rare and severe autoimmune disease characterized by inflammation, tissue damage, and perivenous demyelination in the central nervous system (CNS). As an expert in drug and therapy development for autoimmune diseases and inflammation, our company is committed to providing professional AHLE therapeutic development solutions.
Introduction to Acute Hemorrhagic Leukoencephalitis
Acute Hemorrhagic Leukoencephalitis (AHLE) is a neurological disorder characterized by the presence of inflammation, tissue damage, and perivenous demyelination in the CNS. Similar to acute disseminated encephalomyelitis (ADEM), AHLE is associated with lymphocytic infiltration, although to a lesser extent. Notably, AHLE exhibits numerous granulocytes, perivascular hemorrhages, and fibrinoid necrosis, which distinguish it from ADEM.
Aliases for Acute Hemorrhagic Leukoencephalitis
- Acute necrotizing encephalopathy (ANE)
- Hurst's disease
- Acute hemorrhagic encephalomyelitis (AHEM)
- Weston-Hurst syndrome
- Acute necrotizing hemorrhagic leukoencephalitis (ANHLE)
- AHL, or AHL
Fig.1 Histopathological analysis of the left frontal lobe. (Grzonka P., et al., 2020)
Therapy Discovery and Development for Acute Hemorrhagic Leukoencephalitis
Immunomodulatory therapies aim to modulate the immune response in AHLE, reducing inflammation and preventing further tissue damage. These therapies can include the use of corticosteroids, intravenous immunoglobulins (IVIG), and immunosuppressive agents such as cyclophosphamide. Moreover, monoclonal antibodies, such as rituximab, which targets B cells, and natalizumab, which targets integrins involved in immune cell trafficking, have shown promise in other autoimmune diseases and may hold potential for AHLE therapeutics.
Our company specializes in the development and optimization of immunomodulatory therapies and targeted biologic therapies, ensuring their safety and efficacy. If you would like to learn more about our therapy development services, please click on the link below.
Our Services
Developing effective drugs and therapies for AHLE is a complex and challenging endeavor. At our company, we are at the forefront of AHLE drug and therapy development, offering a comprehensive range of services to support this critical research area. Our preclinical research services for AHLE encompass in vitro and animal model studies. AHLE disease models allow us to investigate the underlying mechanisms of AHLE and test potential therapeutic interventions.
TMEV Induced Models
Theiler's murine encephalomyelitis virus (TMEV) belongs to the family Picornaviridae and can cause a persistent infection in the central nervous system. When administered to susceptible mice, TMEV leads to viral replication, inflammation, demyelination, and hemorrhage, mimicking the key pathological features of AHLE.
We develop models using primary neural cells or cell lines derived from the relevant regions of the nervous system. These models are used to investigate the impact of AHLE-associated immune responses on neural cell viability, function, and myelination.
Organoids derived from neural tissues, such as cerebral organoids or brain organoids, can be utilized to investigate the effects of AHLE on neural development, myelination, and the interactions between immune and neural cells.
Our team of experts includes researchers with extensive experience in autoimmune diseases and inflammation, ensuring that we stay at the forefront of scientific advancements. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
Reference
- Grzonka P., et al. "Acute hemorrhagic leukoencephalitis: a case and systematic review of the literature." Frontiers in neurology 11 (2020): 899.